OSR Holdings signs binding term sheet for VXM01 license; up to $815M in milestones

OSR Holdings, Inc.

Vaximm grants BCME exclusive worldwide license to develop and commercialize VXM01; OSRH is primary recipient of milestone payments.
BCME responsible for up to $815M in milestone payments payable to OSRH; OSRH to provide Vaximm $30M development financing facility.
Related-party transaction as BCME is OSRH's largest shareholder; independent fairness opinion required before definitive agreement.
OSRH retains option to issue up to $15M of common stock at $1.00 per share to BCME Fund, exercisable at OSRH's discretion after 6 months.
Royalties from ultimate licensee pass through to OSRH after BCME recovers a negative milestone delta including up to 15% preferred return.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at up to $815.0 million in milestone payments (effective 2026-03-27).

Action: entry
Agreement: license
Counterparty: BCM Europe AG
Value: up to $815.0 million in milestone payments
Effective: 2026-03-27

Exact text from the filing

On March 27, 2026, OSR Holdings, Inc. (the “Company” or “OSRH”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”) relating to a revised global exclusive license arrangement for VXM01.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

OSR Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-039278

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.